Collins FS, Varmus H. A new initiative on precision medicine. N Engl J Med. 2015;372:793–5.
Article
CAS
Google Scholar
Drilon A, Laetsch TW, Kummar S, DuBois SG, Lassen UN, Demetri GD, et al. Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children. N Engl J Med. 2018;378:731–9.
Article
CAS
Google Scholar
Ramalingam SS, Vansteenkiste J, Planchard D, Cho BC, Gray JE, Ohe Y, et al. Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC. N Engl J Med. 2020;382:41–50.
Article
CAS
Google Scholar
Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364:2507–16.
Article
CAS
Google Scholar
Malone ER, Oliva M, Sabatini PJB, Stockley TL, Siu LL. Molecular profiling for precision cancer therapies. Genome Med. 2020;12:8.
Article
Google Scholar
Good BM, Ainscough BJ, McMichael JF, Su AI, Griffith OL. Organizing knowledge to enable personalization of medicine in cancer. Genome Biol. 2014. https://doi.org/10.1186/s13059-014-0438-7.
Ritter DI, Roychowdhury S, Roy A, Rao S, Landrum MJ, Sonkin D, et al. Somatic cancer variant curation and harmonization through consensus minimum variant level data. Genome Med. 2016;8:117.
Article
Google Scholar
Li MM, Datto M, Duncavage EJ, Kulkarni S, Lindeman NI, Roy S, et al. Standards and guidelines for the interpretation and reporting of sequence variants in cancer: a joint consensus recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists. J Mol Diagn. 2017;19:4–23.
Article
CAS
Google Scholar
Andre F, Mardis E, Salm M, Soria J-C, Siu LL, Swanton C. Prioritizing targets for precision cancer medicine. Ann Oncol. 2014;25:2295–303.
Article
CAS
Google Scholar
Meric-Bernstam F, Johnson A, Holla V, Bailey AM, Brusco L, Chen K, et al. A decision support framework for genomically informed investigational cancer therapy. J Natl Cancer Inst. 2015;107(7):djv098. https://doi.org/10.1093/jnci/djv098.
Leichsenring J, Horak P, Kreutzfeldt S, Heining C, Christopoulos P, Volckmar A-L, et al. Variant classification in precision oncology. Int J Cancer. 2019;145:2996–3010.
Article
CAS
Google Scholar
Chakravarty D, Gao J, Phillips SM, Kundra R, Zhang H, Wang J, et al. OncoKB: A Precision Oncology Knowledge Base. JCO Precis Oncol. 2017;2017:PO.17.00011. https://doi.org/10.1200/PO.17.00011.
Griffith M, Spies NC, Krysiak K, McMichael JF, Coffman AC, Danos AM, et al. CIViC is a community knowledgebase for expert crowdsourcing the clinical interpretation of variants in cancer. Nat Genet. 2017;49:170–4.
Article
CAS
Google Scholar
Seva J, Wiegandt DL, Gotze J, Lamping M, Rieke D, Schafer R, et al. VIST - a Variant-Information Search Tool for precision oncology. BMC Bioinformatics. 2019;20:429.
Article
Google Scholar
Pallarz S, Benary M, Lamping M, Rieke D, Starlinger J, Sers C, et al. Comparative analysis of public knowledge bases for precision oncology. JCO Prec Oncol. 2019;3:1–8.
Google Scholar
Wagner AH, Walsh B, Mayfield G, Tamborero D, Sonkin D, Krysiak K, et al. A harmonized meta-knowledgebase of clinical interpretations of somatic genomic variants in cancer. Nat Genet. 2020;52:448–57.
Article
CAS
Google Scholar
Rieke DT, Lamping M, Schuh M, le Tourneau C, Basté N, Burkard ME, et al. Comparison of treatment recommendations by molecular tumor boards worldwide. JCO Prec Oncol. 2018;2:1–14.
Rodon J, Soria J-C, Berger R, Miller WH, Rubin E, Kugel A, et al. Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial. Nat Med. 2019;25:751–8.
Article
CAS
Google Scholar
Massard C, Michiels S, Ferté C, Le Deley M-C, Lacroix L, Hollebecque A, et al. High-throughput genomics and clinical outcome in hard-to-treat advanced cancers: results of the MOSCATO 01 trial. Cancer Discov. 2017;7:586 LP–595.
Article
Google Scholar
Lamping M, Benary M, Leyvraz S, Messerschmidt C, Blanc E, Kessler T, et al. Support of a molecular tumour board by an evidence-based decision management system for precision oncology. Eur J Cancer. 2020;127:41–51.
Article
CAS
Google Scholar
Horak P, Heining C, Kreutzfeldt S, Hutter B, Mock A, Hullein J, et al. Comprehensive genomic and transcriptomic analysis for guiding therapeutic decisions in patients with rare cancers. Cancer Discov. 2021:candisc.0126.2021;11.
Le Tourneau C, Delord J-P, Goncalves A, Gavoille C, Dubot C, Isambert N, et al. Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial. Lancet Oncol. 2015;16:1324–34.
Article
Google Scholar
Sicklick JK, Kato S, Okamura R, Schwaederle M, Hahn ME, Williams CB, et al. Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT study. Nat Med. 2019;25:744–50.
Article
CAS
Google Scholar
Massard C, Michiels S, Ferté C, le Deley M-C, Lacroix L, Hollebecque A, et al. High-throughput genomics and clinical outcome in hard-to-treat advanced cancers: results of the MOSCATO 01 trial; 2017. https://doi.org/10.1158/2159-8290.CD-16-1396.
Book
Google Scholar
Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015;372:2509–20.
Article
CAS
Google Scholar
Koopman B, Groen HJ, Ligtenberg MJ, Grünberg K, Monkhorst K, de Langen AJ, et al. Multicenter comparison of molecular tumor boards in The Netherlands: definition, composition, methods, and targeted therapy recommendations; 2020. https://doi.org/10.1002/onco.13580.
Book
Google Scholar
Klauschen F, Andreeff M, Keilholz U, Dietel M, Stenzinger A. The combinatorial complexity of cancer precision medicine. Oncoscience. 2014;1:504–9.
Article
Google Scholar
Horak P, Griffith M, Danos AM, Pitel BA, Madhavan S, Liu X, et al. Standards for the classification of pathogenicity of somatic variants in cancer (oncogenicity): joint recommendations of Clinical Genome Resource (ClinGen), Cancer Genomics Consortium (CGC), and Variant Interpretation for Cancer Consortium (VICC). Genet Med. 2022. https://doi.org/10.1016/j.gim.2022.01.001.
Kato S, Kim KH, Lim HJ, Boichard A, Nikanjam M, Weihe E, et al. Real-world data from a molecular tumor board demonstrates improved outcomes with a precision N-of-One strategy. Nat Commun. 2020;11:1–9.
Article
Google Scholar
Pezo RC, Bedard PL. Definition: Translational and personalised medicine, biomarkers, pharmacodynamics. In: ESMO Handbook of Translational Research; 2015.
Google Scholar
Vijaymeena MK, Kavitha K. A survey on similarity measures in text mining. Machine Learn Appl Int J (MLAIJ). 2016;3.